Eli Lilly & Co. said its experimental Alzheimer’s treatment slowed the decline of cognition in some patients while failing to meet the primary goals of two large trials. The shares rose.
Lilly’s drug, solanezumab, delayed the worsening of mental loss in a sub-analysis of patients in the earliest stage of the disease, the Indianapolis-based company wrote in a statement today. The medicine didn’t restore thinking, memory or daily activities in any of the groups studied.
